Why the study?
Does systemic lentiviral delivery of ACE2 protect against angiotensin II-induced cardiac hypertrophy and fibrosis in rats?
Does systemic lentiviral delivery of ACE2 protect against angiotensin II-induced cardiac hypertrophy and fibrosis in rats?
Answers are grounded in this paper and cite their sources.
Overexpression of ACE2 via lentiviral delivery protects against angiotensin II-induced cardiac hypertrophy and fibrosis in a rat model, highlighting its potential as a therapeutic target.
Angiotensin converting enzyme 2 (ACE2), a newly discovered member of the renin-angiotensin system (RAS), is a potential therapeutic target for the control of cardiovascular disease owing to its key role in the formation of vasoprotective peptides from angiotensin II. The aim of the present study was to evaluate whether overexpression of ACE2 could protect the heart from angiotensin II-induced hypertrophy and fibrosis. Lentiviral vector encoding mouse ACE2 (lenti-mACE2) or GFP was injected intracardially in 5-day-old Sprague-Dawley rats. This resulted in expression of mACE2 in cardiac tissue for the duration of the study. Infusion of 200 ng kg-1 min-1 angiotensin II for 4 weeks resulted in an 80 mmHg increase in systolic blood pressure, a significant increase in the heart weight to body weight ratio (HW:BW), and marked myocardial fibrosis in control rats. Transduction with lenti-mACE2 resulted in significant attenuation of the increased HW:BW and myocardial fibrosis induced by angiotensin II infusion. These observations demonstrate that ACE2 overexpression results in protective effects on angiotensin II-induced cardiac hypertrophy and fibrosis.
No takes yet. Share an insight, caveat, or question.
Huentelman et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: